NEMLUVIO relieves itch fast, with skin healing that lasts1‑3

Approved in atopic dermatitis and prurigo nodularis4

NEMLUVIO FIRST and ONLY to BLOCK IL31RA.
      
NEMLUVIO first and only to block IL-31RA. Itch, Inflammation, Skin Barrier Dysfunction, and Fibrosis.

Actor portrayals.

  • UNIQUE 
    MOA4,5

  • FAST ITCH RELIEF‍—
    as soon as 48 hours* 
    in some patients1

  • LASTING  SKIN 
    HEALING2,3

  • FAVORABLE 
    SAFETY PROFILE4

  • Q4W DOSING 
    FROM THE START4

PP-NRS response was achieved at 48 hours (AD: 10.7% with NEMLUVIO + TCS/TCI vs 2.9% with placebo + TCS/TCI; PN: 17.2% vs 3.7% with placebo). Data from pooled post-hoc analysis of daily PP-NRS improvement reported in Phase 3 clinical studies (ARCADIA 1 and 2, OLYMPIA 1 and 2). PP-NRS response defined as a ≥4-point improvement from baseline. No conclusions regarding efficacy should be made based on these results.1

Co-Pay Assistance

Eligible patients may pay as little as $0

The Co-Pay program helps commercially insured patients reduce or eliminate out-of-pocket costs and improve affordability.

ENROLL YOUR PATIENTS 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.